These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8355457)

  • 1. Renal osteodystrophy in diabetic patients.
    Pei Y; Hercz G; Greenwood C; Segre G; Manuel A; Saiphoo C; Fenton S; Sherrard D
    Kidney Int; 1993 Jul; 44(1):159-64. PubMed ID: 8355457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for renal osteodystrophy: a multivariant analysis.
    Pei Y; Hercz G; Greenwood C; Segre G; Manuel A; Saiphoo C; Fenton S; Sherrard D
    J Bone Miner Res; 1995 Jan; 10(1):149-56. PubMed ID: 7747622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated bone aluminum and suppressed parathyroid hormone levels in hypercalcemic dialysis patients.
    Piraino B; Chen T; Puschett JB
    Am J Nephrol; 1989; 9(3):190-7. PubMed ID: 2757078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adynamic bone disease with negative aluminium staining in predialysis patients: prevalence and evolution after maintenance dialysis.
    Hernandez D; Concepcion MT; Lorenzo V; Martinez ME; Rodriguez A; De Bonis E; Gonzalez-Posada JM; Felsenfeld AJ; Rodriguez M; Torres A
    Nephrol Dial Transplant; 1994; 9(5):517-23. PubMed ID: 7522307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal osteodystrophy in patients on hemodialysis for more than 10 years.
    Piraino BM; Rault R; Dominguez JH; Puschett JB
    Miner Electrolyte Metab; 1986; 12(5-6):390-6. PubMed ID: 3807834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function.
    Hercz G; Pei Y; Greenwood C; Manuel A; Saiphoo C; Goodman WG; Segre GV; Fenton S; Sherrard DJ
    Kidney Int; 1993 Oct; 44(4):860-6. PubMed ID: 8258962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal osteodystrophy in pre-dialysis patients: ethnic difference?
    Shin SK; Kim DH; Kim HS; Shin KT; Ma KA; Kim SJ; Kwak YS; Ha SK; Sherrard DJ
    Perit Dial Int; 1999; 19 Suppl 2():S402-7. PubMed ID: 10406554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital.
    Mathias R; Salusky I; Harman W; Paredes A; Emans J; Segre G; Goodman W
    J Am Soc Nephrol; 1993 Jun; 3(12):1938-46. PubMed ID: 8338926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled study of renal osteodystrophy in patients undergoing dialysis. Improved response to continuous ambulatory peritoneal dialysis compared with hemodialysis.
    Shusterman NH; Wasserstein AG; Morrison G; Audet P; Fallon MD; Kaplan F
    Am J Med; 1987 Jun; 82(6):1148-56. PubMed ID: 3605132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients.
    Pei Y; Hercz G; Greenwood C; Sherrard D; Segre G; Manuel A; Saiphoo C; Fenton S
    Kidney Int; 1992 May; 41(5):1374-82. PubMed ID: 1614052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings.
    Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG
    Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptomatic hypercalcemia in a diabetic patient undergoing continuous ambulatory peritoneal dialysis: value of bone biopsy in the diagnosis and management.
    Frazao J; Coburn JW
    Am J Kidney Dis; 1995 Nov; 26(5):831-5. PubMed ID: 7485141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low turnover bone disease is the more common form of bone disease in CAPD patients.
    Rodriguez-Perez JC; Plaza C; Torres A; Vega N; Anabitarte A; Fernandez A; Lorenzo V; Hortal L; Palop L
    Adv Perit Dial; 1992; 8():376-80. PubMed ID: 1361827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The early effects of aluminium deposition and dialysis on bone in chronic renal failure: a cross-sectional bone-histomorphometric study.
    Dahl E; Nordal KP; Halse J; Flatmark A
    Nephrol Dial Transplant; 1990; 5(6):449-56. PubMed ID: 2122323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone histomorphometry of renal osteodystrophy in diabetic patients.
    Andress DL; Hercz G; Kopp JB; Endres DB; Norris KC; Coburn JW; Sherrard DJ
    J Bone Miner Res; 1987 Dec; 2(6):525-31. PubMed ID: 3455634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of in-center daily hemodialysis upon mineral metabolism and bone disease in end-stage renal disease patients.
    Lugon JR; André MB; Duarte ME; Rembold SM; Cruz E
    Sao Paulo Med J; 2001 May; 119(3):105-9. PubMed ID: 11391452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
    Tzamaloukas AH
    Med Clin North Am; 1990 Jul; 74(4):961-74. PubMed ID: 2195265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal osteodystrophy in dialysis patients as estimated by three-point bone densitometry].
    Kucharska E; Stompór T; Sułowicz W; Drozdz M; Kaczmarczyk I; Szymczakiewicz-Multanowska A; Chruściel B; Kraśnicka M
    Przegl Lek; 2000; 57(6):334-9. PubMed ID: 11107868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.